FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first...
Main Authors: | Iason Psilopatis, Christos Damaskos, Anna Garmpi, Panagiotis Sarantis, Evangelos Koustas, Efstathios A. Antoniou, Dimitrios Dimitroulis, Gregory Kouraklis, Michail V. Karamouzis, Kleio Vrettou, Georgios Marinos, Konstantinos Kontzoglou, Nikolaos Garmpis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/3/2685 |
Similar Items
-
The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy
by: Iason Psilopatis, et al.
Published: (2023-08-01) -
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
by: Christos Damaskos, et al.
Published: (2024-01-01) -
Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review
by: Christos Damaskos, et al.
Published: (2022-11-01) -
Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
by: Nikolaos Garmpis, et al.
Published: (2022-10-01) -
The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
by: Iason Psilopatis, et al.
Published: (2023-04-01)